On June 24, 2026, Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration approved TRYNGOLZA (Olezarsen) to lower triglycerides and reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia.
This treatment was previously approved for Familial Chylomicronemia Syndrome (FCS), a rare genetic form of severe hypertriglyceridemia. This approval expands its use to adults with severe hypertriglyceridemia.
Read the official Ionis press release for complete details: https://ir.ionis.com/news-releases/news-release-details/tryngolzar-olezarsen-approved-fda-first-and-only-treatment
To learn more about high triglycerides, severe hypertriglyceridemia, and pancreatitis, watch our webinar with Dr. Andres Gelrud: High Triglycerides & Pancreatitis: Causes, Diagnosis & Treatments
Read more about Triglycerides, sHTG, FCS, and Pancreatitis on our webpage.
About Mission: Cure
At Mission: Cure, we are dedicated to finding effective treatments and, ultimately, a cure for pancreatitis. Through patient education, research, and advocacy, we strive to improve the lives of those affected by this condition.
Get Updates in Your Inbox
Stay up-to-date on the latest Mission: Cure news and developments in pancreatitis care by signing up for our newsletter.